NCT06793956View on ClinicalTrials.gov

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2030

Conditions
Extranodal Natural Killer/T Cell Lymphoma
Interventions
DRUG

Sintilimab and Linperlisib Combination Treatment

Sintilimab administered via intravenous infusion; Linperlisib administered orally.

Trial Locations (1)

51000

RECRUITING

Sun Yat-sen Universitiy Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER